Methodology
Medicine origin: what we can tell you, and what nobody can
We publish this before anyone asks, because the limits of this data are more interesting than the data itself. About one in three medicines yields a country. For the rest, no one — not us, not you, not the pharmacist — can find out from public records. That gap is entirely lawful, and this page explains why.
What the numbers actually are
We processed every identifiable medicine, supplement and over-the-counter product across the pharmacy retailers we support, and tried to resolve each one to a manufacturing country. Most of the time we could not, because nothing in the public record says.
| Outcome | Products | Share |
|---|---|---|
| Country and facility role, from a named manufacturer matched to the FDA facility registry | 14,422 | 16.6% |
| Country stated on the label by the manufacturer | 10,656 | 12.3% |
| Private label — the maker is deliberately undisclosed | 4,123 | 4.8% |
| Nothing disclosed at all | 54,756 | 63.2% |
| Not yet classified | 2,662 | 3.1% |
| Identifiable products processed | 86,619 | 100% |
Figures as of 11 August 2026. The four resolved outcomes account for 96.9% of the corpus; the remaining 3.1% has not been classified and we show it rather than folding it into a category it may not belong to. Figures as stated, They move as the federal registries are republished; we restate them here rather than quoting a number we no longer hold.
The 63.2% is the finding worth sitting with. It is not a limitation of our method — it is the condition of the market. Nearly two-thirds of what is on a pharmacy shelf names nobody who could be asked where it was made.
Where a facility does resolve, we can say what it does
This is the part no other consumer-facing source offers. A manufacturing site registered with the FDA carries the operations it is licensed to perform, so where we match one we can distinguish between a plant that produced the finished dose, one that made the active ingredient, and one that only did packaging and labelling. Those are very different claims about a product, and they are routinely collapsed into a single "made in" elsewhere.
What "made in" means on a medicine
It means the pill, not the medicine. When we report a country for a drug product, we are reporting where the finished dose form was produced — the tablet was pressed, the capsule filled, the solution bottled. We are not reporting where the molecule came from.
The FDA and US Customs define origin differently for the same product, so we publish separate lines rather than reconciling them into one country that would be wrong under at least one definition.
What we never know
- Active-ingredient origin. Not for any product, ever. The FDA collects this and does not publish it per product. A tablet finished in Ireland can be built on an ingredient made anywhere, and no public database connects the two. Anyone claiming full supply-chain transparency for a consumer medicine is overstating what exists.
- Who makes a store brand. CVS, Walgreens, Rite Aid and supermarket own-labels name no manufacturer. We can tell you the retailer does not disclose it. We cannot tell you who it is.
- Anything at the brand level. Coverage is per product. Two products from one company can resolve differently, and a generic may change manufacturer between refills. A result for one product is never a statement about the brand.
Why the gap is lawful
None of this is a failure of enforcement. The absence is written into the rules, which is what makes it worth knowing about.
A distributor's name is enough
21 CFR 201.1 requires a drug label to carry the name of the "manufacturer, packer, or distributor." Printing only the distributor is fully compliant. That is why a bottle can name an office in New Jersey for a drug made on the other side of the world.
Pills are exempt from origin marking
19 CFR 134.33 exempts drugs imported "in capsules, pills, tablets, lozenges, or troches" from country-of-origin marking. Only the bulk container has to be marked — and that container is opened behind the pharmacy counter and discarded.
The law that would change this has not passed
The CLEAR LABELS Act, introduced in February 2026, would require origin disclosure on prescription labels. It has been introduced. It is not law, and we will not describe it as one.
Where this works, and where we do not apply it
- Supplements and over-the-counter products are where this is most useful. They are ordinary product listings, the category is enormous, and disclosure is worst there.
- We do not score prescription drugs. Prescriptions are dispensed rather than listed, the manufacturer can change between refills, and the cost of a wrong answer is categorically higher.
- Some pharmacy pages carry no drug data at all. Where a retailer's product page publishes no ingredient text, dose or product code, a medicine there is scored as an ordinary product, with no medicine-specific answer.
If we get one wrong
Every score cites its sources, and anyone can contest one — no account required. Corrections from a verified source override our answer and stay overridden. See corrections for how that works and what we have changed.
Nothing here is medical advice, and nothing here should be used to choose or avoid a medication. Talk to a pharmacist or a physician. Origin is one fact about a product; it is not a safety or efficacy judgment, and we do not present it as one.